Kodiak Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $9.77 Mil. Kodiak Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $71.86 Mil. Kodiak Sciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $265.78 Mil.
Kodiak Sciences's debt to equity for the quarter that ended in Dec. 2023 was 0.31.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Kodiak Sciences's Debt-to-Equity or its related term are showing as below:
KOD'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.14 Med: 0.09 Max: 0.31
Current: 0.31
During the past 8 years, the highest Debt-to-Equity Ratio of Kodiak Sciences was 0.31. The lowest was -0.14. And the median was 0.09.
Kodiak Sciences Debt-to-Equity Historical Data
The historical data trend for Kodiak Sciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
Kodiak Sciences Annual Data
|
|
Trend |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
0.01 |
0.09 |
0.12 |
0.20 |
0.31 |
|
Kodiak Sciences Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.20 |
0.22 |
0.25 |
0.28 |
0.31 |
Competitive Comparison
For the Biotechnology subindustry, Kodiak Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kodiak Sciences Debt-to-Equity Distribution
For the Biotechnology industry and Healthcare sector, Kodiak Sciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Kodiak Sciences's Debt-to-Equity falls into.
Kodiak Sciences Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Kodiak Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Kodiak Sciences's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kodiak Sciences (Kodiak Sciences) Business Description
Traded in Other Exchanges
Address
1200 Page Mill Road, Palo Alto, CA, USA, 94304
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Executives
| Jason Ehrlich |
officer: See Remarks |
1200 PAGE MILL ROAD, PALO ALTO CA 94304 |
| John A. Borgeson |
officer: See Remarks |
1200 PAGE MILL ROAD, PALO ALTO CA 94304 |
| Baker Bros. Advisors Lp |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Victor Perlroth |
director, 10 percent owner, officer: Chairman, President and CEO |
1200 PAGE MILL ROAD, PALO ALTO CA 94304 |
| Julian Baker |
director, 10 percent owner |
BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
| Felix Baker |
director, 10 percent owner |
BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
| Baker Brothers Life Sciences Lp |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| L.p. 667, |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Baker Bros. Advisors (gp) Llc |
director, 10 percent owner |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Charles A Bancroft |
director |
BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543 |
| Hong Liang |
officer: See Remarks |
2631 HANOVER STREET, PALO ALTO CA 94304 |
| Richard S Levy |
director |
860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
| Taiyin Yang |
director |
2631 HANOVER STREET, PALO ALTO CA 94304 |
| Robert Profusek |
director |
P.O. BOX 696000, SAN ANTONIO TX 78269-6000 |
| Bassil I Dahiyat |
director |
C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016 |
Kodiak Sciences (Kodiak Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KOD has been successfully added to your